Xu Jiandong 4

What Happened
Xu Jiandong, Chief Financial Officer of Estrella Immunopharma (ESLA), made three open-market purchases of company stock between Sept. 11 and Oct. 7, 2025. He acquired a total of 2,100 shares: 100 shares at $1.04 ($104), 1,000 shares at $1.16 ($1,160), and 1,000 shares at $1.33 ($1,330), for a combined cost of $2,594. These transactions are purchases (transaction code P), which represent insider buying rather than sales.

Key Details

• Transaction dates and prices:
  • 2025-09-11 — 100 shares @ $1.04 = $104
  • 2025-09-22 — 1,000 shares @ $1.16 = $1,160
  • 2025-10-07 — 1,000 shares @ $1.33 = $1,330
• Total purchased: 2,100 shares for $2,594.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote F1: Some securities are held by the reporting person's spouse; the reporting person disclaims beneficial ownership of those shares.
• Filing timeliness: The Form 4 was filed on 2026-04-29 reporting transactions from Sept–Oct 2025, indicating a late filing. Late filings reduce the timeliness of disclosure and can carry regulatory consequences.

Context

• Purchases (P) are straightforward open-market buys — not option exercises, awards, or gifts. Such purchases are factual disclosures of insider buying; they do not, by themselves, prove a change in company outlook.
• For retail investors, insider purchases can be one data point to consider alongside company fundamentals and news; note that the filing delay limits the usefulness of the timing information.